HCP
84
-2
VRSN
48
2
ETN
78
-2
EL
34
-16
RCL
65
-3
MRO
40
-2
MMM
35
5
KHC
36
-14
DOV
76
-2
YUM
57
-9
HBAN
54
3
NWL
37
-4
DFS
56
-6
BA
43
3
OMC
58
3
KLAC
58
-5
PAYX
41
-3
HP
30
-3
AAPL
59
-2
EQT
53
-6
HCP
84
-2
VRSN
48
2
ETN
78
-2
EL
34
-16
RCL
65
-3
MRO
40
-2
MMM
35
5
KHC
36
-14
DOV
76
-2
YUM
57
-9
HBAN
54
3
NWL
37
-4
DFS
56
-6
BA
43
3
OMC
58
3
KLAC
58
-5
PAYX
41
-3
HP
30
-3
AAPL
59
-2
EQT
53
-6
Financhill
Back

Sorrento Therapeutics 10K Form

Sell
44

SRNE
Sorrento Therapeutics

Last Price:
0.0100
Seasonality Move:
15.42%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRNE News And Ratings

See the #1 stock for the next 7 days that we like better than SRNE

SRNE Financial Statistics

Sales & Book Value

Annual Sales: $62.84M
Cash Flow: $-55.8M
Price / Cash Flow: 0
Annual Sales: $-0.37
Price / Book: 0

Profitability

EPS (TTM): -1.12000
Net Income (TTM): $-548.1M
Gross Margin: $29.39M
Return on Equity: 0%
Return on Assets: -103.91%

Sorrento Therapeutics Earnings Forecast

Key Sorrento Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 15 years for SRNE is 46.77%.
  • The Selling, General & Administrative Expenses for SRNE have been equal to 290.17% of Gross Profit Margin.
  • The Research & Development expenses have been 352.05% of Revenue.
  • The Interest Expense is -1.50% of Operating Income.
  • The Net Earning history of SRNE is -911.60% of Total Revenues.
  • Per Share Earnings over the last 20 years have been positive in 8 years.

Sorrento Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRNE
CUSIP: 83587F
Website: sorrentotherapeutics.com

Debt

Debt-to-Equity Ratio: -0.69
Current Ratio: 0.5
Quick Ratio: 0.43

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

SRNE Technical Analysis vs Fundamental Analysis

Sell
44
Sorrento Therapeutics (SRNE) is a Sell

Is Sorrento Therapeutics a Buy or a Sell?